Innovent Biologics (suzhou) Co. Ltd.

This early-stage trial is testing a new drug called IBI115, alone or with other treatments, in 150 people with advanced small cell lung cancer. The main goals are to check safety, find the right dose, and look for early signs that the drug might help control the disease.

This study tests whether adding a new drug called IBI343 to standard immunotherapy and chemotherapy can help eliminate stomach cancer more effectively before and after surgery. It involves 90 adults with a specific type of stomach cancer that has not spread widely. Participants w…

This phase 2 study tests a new drug called IBI343 combined with two chemotherapy drugs (gemcitabine and nab-paclitaxel) in people with advanced stomach, gastroesophageal junction, or pancreatic cancers that have a specific protein (CLDN18.2). The goal is to see if the combination…

This Phase 3 trial tests a drug called IBI362 in people with mild to moderate high blood pressure who are also overweight or obese. Participants receive weekly injections of either the drug or a placebo for 48 weeks. The main goal is to see if IBI362 lowers blood pressure more th…

This early-phase study tests a new drug called IBI343 in people with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. About 470 participants will take part in mul…

This early-stage trial tests a new drug called IBI3013, which blocks a protein (IL-15) involved in immune attacks. It includes 160 people: healthy volunteers first, then people with active vitiligo or severe alopecia areata. The main goal is to check safety and how the drug moves…

This Phase 3 trial tests a new injectable drug called IBI306 in 198 Chinese adults with non-familial high cholesterol and mixed high lipids. Participants receive either IBI306 or a placebo every 2 or 4 weeks for 12 weeks. The main goal is to see how much the drug lowers LDL (bad)…

This study tests a new drug called IBI356 in about 400 adults with moderate to severe atopic dermatitis (eczema). Participants receive either IBI356, dupilumab (an existing treatment), or a placebo by injection. The main goal is to see if IBI356 reduces eczema severity and itchin…

This study tests an experimental drug called IBI3014 in 250 adults with advanced solid tumors that cannot be removed by surgery. The drug is given by IV every 3 weeks at different doses. The main goals are to find the safest dose and to see if the drug can shrink tumors. This is …

This study tests a drug called IBI362 in 180 Chinese adolescents aged 12 to 17 who are obese or overweight and haven't lost enough weight with diet and exercise alone. Participants will receive either the drug or a placebo to see if it helps reduce body mass index (BMI) safely. T…

This study tests a new medicine, IBI362, in 165 adults with MASH, a serious fatty liver disease that can lead to scarring. Participants will receive either a low dose, high dose, or a placebo for 60 weeks. The main goal is to see if the drug can improve liver health without makin…

This Phase 3 trial tests IBI311 (teprotumumab) in 111 people with inactive thyroid eye disease. The main goal is to see if the drug can reduce eye bulging by at least 2 mm after 24 weeks. Participants receive either the drug or a placebo, and the study lasts up to 64 weeks.

This phase 2 trial tests whether adding an experimental drug (IBI363) or the approved drug Keytruda to standard chemotherapy can better shrink tumors before surgery in people with stage IB to III non-squamous lung cancer. About 170 participants will be randomly assigned to one of…

This study tests an experimental drug called IBI3002 in 120 adults with moderate to severe atopic dermatitis (eczema). The goal is to see if it reduces skin redness, thickness, and itching better than a placebo over 16 weeks. Participants will be randomly assigned to receive eith…